Kiniksa Pharmaceuticals
KNSA
41 hedge funds and large institutions have $298M invested in Kiniksa Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
117.03% more ownership
Funds ownership: 0% → 117.03% (+117%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$104M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$54.3M |
| 3 |
DM
Deerfield Management
New York
|
+$22.2M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$21.2M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$16.7M |
Top Sellers
KNSA Hedge Fund Activity: Q2 2018 in Review
41 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2018, worth a combined $298M.
Buyers outnumbered sellers: 41 funds opened new KNSA positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Hillhouse Investment Management, opening a new position worth an estimated $104M.
- 41 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $298M of Kiniksa Pharmaceuticals stock for Q2 2018.
- 41 funds opened new Kiniksa Pharmaceuticals positions in Q2 2018 and 0 closed out, a net change of +41 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q2 2018 was Hillhouse Investment Management, an estimated $104M added.
Based on aggregated 13F filings for Q2 2018.